- Home
- IBTA vs CERT Comparison
IBTA vs CERT Comparison
Compare IBTA & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBTA
- CERT
- Stock Information
- Founded
- IBTA 2011
- CERT 2008
- Country
- IBTA United States
- CERT United States
- Employees
- IBTA N/A
- CERT N/A
- Industry
- IBTA
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- IBTA
- CERT Technology
- Exchange
- IBTA Nasdaq
- CERT Nasdaq
- Market Cap
- IBTA 1.6B
- CERT 1.6B
- IPO Year
- IBTA 2024
- CERT 2020
- Fundamental
- Price
- IBTA $67.03
- CERT $9.95
- Analyst Decision
- IBTA Strong Buy
- CERT Buy
- Analyst Count
- IBTA 9
- CERT 7
- Target Price
- IBTA $89.67
- CERT $15.92
- AVG Volume (30 Days)
- IBTA 277.7K
- CERT 1.2M
- Earning Date
- IBTA 11-13-2024
- CERT 11-06-2024
- Dividend Yield
- IBTA N/A
- CERT N/A
- EPS Growth
- IBTA N/A
- CERT N/A
- EPS
- IBTA 0.48
- CERT N/A
- Revenue
- IBTA $368,548,000.00
- CERT $372,797,000.00
- Revenue This Year
- IBTA $19.37
- CERT $10.39
- Revenue Next Year
- IBTA $20.75
- CERT $10.57
- P/E Ratio
- IBTA $138.40
- CERT N/A
- Revenue Growth
- IBTA 74.91
- CERT 5.62
- 52 Week Low
- IBTA $41.87
- CERT $9.88
- 52 Week High
- IBTA $110.95
- CERT $19.87
- Technical
- Relative Strength Index (RSI)
- IBTA N/A
- CERT 41.17
- Support Level
- IBTA N/A
- CERT $10.54
- Resistance Level
- IBTA N/A
- CERT $11.37
- Average True Range (ATR)
- IBTA 0.00
- CERT 0.39
- MACD
- IBTA 0.00
- CERT 0.03
- Stochastic Oscillator
- IBTA 0.00
- CERT 23.86
About IBTA Ibotta Inc. Class A Common Stock
Ibotta Inc is a performance marketing platform. It allows CPG brands to deliver digital promotions to consumers through a single, convenient network called the Ibotta Performance Network (IPN).
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.